





dreams




Sleep Deprivation



Adults Have Trouble Sleeping



Teenagers Are Sleep Deprived



College Students Lack Sleep

TAM

\$36.5 Billion

Supplementary Sleep Aids Market

SAM

\$20.52 Billion

Sleep-tech market

SOM

~\$26.3 Million

Sleep-tech NVNS market

Solution



Minimal Risk



Comfortable & User-Friendly



Improved Sleep Depth and Stability

Active Sleep Mask

The only device that helps while sleeping



Made with GAMMA



Neurophysiological Mechanism

- Activates the parasympathetic nervous system, lowering stress levels and promoting relaxation.
- Stimulates the brain to produce calming alpha waves, aiding in relaxation before sleep.
- Increases levels of neurotransmitters that are essential for sleep regulation.
- Enhances the production of hormones that generates sleep.

Go To Market

1

Early Adopters POC

2

510(k) - Insomnia

3

Collaboration With Sleep Clinics

4


Distribution Partnerships

Competitive landscape



Competitor	Product	Treatment
tVNS		Depression, Epilepsy, Migraines, Prader-Willi-Syndrome
CES Ultra		Relieve Anxiety and Insomnia
IB Stim		Opiate Withdrawal

Billion Dollar Roadmap

The Neuromodulation Suite



Scientific Proof



Study (Year)	Population	Stimulation Protocol	Outcomes
Zhang et al., 2024 (JAMA Netw Open)	72 adults with chronic insomnia (PSQI ≥ 8)	4/20 Hz alternating “dilatational” wave, 0.2 ms pulse width, intensity 0.8–1.5 mA (max tolerable); 30 min 2x daily , 5 days/week for 8 weeks.	PSQI improved by ~8.2 points from baseline (vs ~3.9 in sham); a 4.2-point greater reduction with taVNS ($P<0.001$). Insomnia severity, sleep latency, duration, and daytime dysfunction all improved. Benefits sustained at 20 weeks; only mild side effects (ear discomfort).
Zhang et al., 2023 (Brain Sci)	60 patients with high-altitude insomnia (randomized to taVNS, sham, or CBT-I)	taVNS via ear electrode, ~20 Hz (parameters per text); 30 min daily for 4 weeks.	PSQI, ISI, and GAD-7 (anxiety) scores decreased significantly after 4 weeks taVNS, more than in sham or CBT-I groups. Polysomnography showed shorter sleep latency and longer deep sleep with taVNS. Conclusion: taVNS effectively improved sleep quality and reduced anxiety in high-altitude insomnia.
Srinivasan et al., 2024	42 elderly healthcare workers with anxiety and poor sleep (post-COVID era)	30 min 3x/week for 4 weeks; taVNS (auricular) vs control (Jacobson's progressive muscle relaxation).	After 4 weeks, taVNS group had significantly better sleep quality and lower anxiety than control ($p = 0.001$). Authors conclude taVNS is an effective intervention for stress-related insomnia and anxiety in older adults.

The Team



Medical Experts



Felix Benninger, MD

Clinical Neurology; Electrophysiological Techniques;
Epileptogenesis



Research Specialists




Nir Cafri, M.Sc.

Sr. Data Scientist.


Questions?



First Personalized tVNS



Competition

Competitor	Product	Treatment / Use Case
Neurovalens		Vestibular + auricular stimulation for weight loss, sleep, anxiety, and diabetes – CE/UKCA-cleared
Nervana		Mood enhancement, stress reduction, uses music-synced taVNS
Parasym		taVNS for digestive health, tinnitus, and general autonomic modulation
Nemos (Cerbomed)		Clinical-grade taVNS for epilepsy and depression (CE-certified in EU)
tVNS Technologies		CE-approved for epilepsy, depression, pain; non-invasive ear electrode
ElectroCore		Cervical (not auricular) VNS for cluster headaches and migraines (FDA cleared)
Earable Neuroscience		Sleep improvement via EEG-based audio stimulation (not VNS) – borderline case
Spark Biomedical		FDA-cleared taVNS for opioid withdrawal and pediatric NAS treatment